Highlights
- Market Cap
- $296.29M
- Enterprise Value
- $255.91M
- EPS (TTM)
- $1.14
- PE Ratio
- 3.92
- Total Revenue (TTM)
- $5.82M
- Gross Profit (TTM)
- $4.59M
- EBITDA (TTM)
- $74.37M
- Year Range
- $3.93 - $7.54
- Target Price
- $17.00
- ROA (TTM)
- 32.42%
- ROE (TTM)
- 44.71%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Abeona Therapeutics Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Abeona Therapeutics Inc. (ABEO) has returned -14.99% so far this year and -5.88% over the past 12 months. Over the last ten years, ABEO has returned -24.12% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.
Abeona Therapeutics Inc.
- 1D
- 5.91%
- 1M
- -12.50%
- YTD
- -14.99%
- 6M
- -15.15%
- 1Y
- -5.88%
- 3Y*
- 16.68%
- 5Y*
- -37.37%
- 10Y*
- -24.12%
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Sep 19, 1980, ABEO's average daily return is +0.12%, while the average monthly return is +1.17%. At this rate, your investment would double in approximately 5.0 years.
Historically, 41% of months were positive and 59% were negative. The best month was Dec 1995 with a return of +183.3%, while the worst month was Sep 2020 at -56.6%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 9 months.
On a daily basis, ABEO closed higher 36% of trading days. The best single day was Oct 6, 2006 with a return of +120.8%, while the worst single day was Jun 7, 1995 at -62.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -3.42% | 0.59% | -12.50% | -14.99% | |||||||||
| 2025 | -0.54% | -5.42% | -9.16% | 37.82% | -4.88% | -8.97% | 12.15% | 7.22% | -22.69% | -8.90% | 5.41% | 3.94% | -5.39% |
| 2024 | -18.76% | 69.53% | 5.07% | -42.90% | 5.80% | -3.20% | 15.57% | 16.33% | 10.88% | 1.42% | -0.31% | -12.83% | 11.18% |
| 2023 | -18.18% | -9.13% | 23.14% | 8.87% | 0.65% | 30.42% | -15.14% | 29.53% | -4.97% | -9.26% | 25.65% | 4.37% | 62.66% |
| 2022 | -24.27% | 1.10% | 22.09% | -34.44% | -18.50% | 23.59% | -23.85% | -8.08% | -16.48% | 50.99% | -18.08% | -18.09% | -63.44% |
| 2021 | 21.66% | 26.70% | -22.31% | -5.85% | -6.78% | -5.45% | -21.79% | 8.20% | -15.15% | -27.47% | -15.18% | -51.09% | -78.54% |
Benchmark Metrics
Abeona Therapeutics Inc. has an annualized alpha of 25.08%, beta of 0.68, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since September 22, 1980.
- This stock participated in 177.60% of S&P 500 Index downside but only 30.75% of its upside — more exposed to losses than it benefited from rallies.
- Beta of 0.68 may look defensive, but with R² of 0.01 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 25.08%
- Beta
- 0.68
- R²
- 0.01
- Upside Capture
- 30.75%
- Downside Capture
- 177.60%
Return for Risk
Risk / Return Rank
ABEO ranks 35 for risk / return — below 35% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Abeona Therapeutics Inc. (ABEO) and compare them to a chosen benchmark (S&P 500 Index).
| ABEO | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.10 | 0.90 | -0.99 |
Sortino ratioReturn per unit of downside risk | 0.31 | 1.39 | -1.07 |
Omega ratioGain probability vs. loss probability | 1.04 | 1.21 | -0.18 |
Calmar ratioReturn relative to maximum drawdown | -0.23 | 1.40 | -1.63 |
Martin ratioReturn relative to average drawdown | -0.42 | 6.61 | -7.03 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore ABEO risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Abeona Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Abeona Therapeutics Inc. was 100.00%, occurring on Feb 24, 2023. The portfolio has not yet recovered.
The current Abeona Therapeutics Inc. drawdown is 100.00%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -100% | May 22, 1981 | 10529 | Feb 24, 2023 | — | — | — |
| -28.57% | Nov 21, 1980 | 25 | Dec 29, 1980 | 13 | Jan 16, 1981 | 38 |
| -20.27% | Feb 3, 1981 | 12 | Feb 19, 1981 | 28 | Mar 31, 1981 | 40 |
| -16.25% | Apr 28, 1981 | 5 | May 4, 1981 | 12 | May 20, 1981 | 17 |
| -9.86% | Jan 20, 1981 | 1 | Jan 20, 1981 | 8 | Jan 30, 1981 | 9 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Abeona Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Abeona Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for ABEO, comparing it with other companies in the Biotechnology industry. Currently, ABEO has a P/E ratio of 3.9. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ABEO relative to other companies in the Biotechnology industry. Currently, ABEO has a P/S ratio of 48.0. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ABEO in comparison with other companies in the Biotechnology industry. Currently, ABEO has a P/B value of 1.9. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |